Vedolizumab for the Prevention of Postoperative Recurrence of Crohn's disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol 2024 Nov 18;[EPub Ahead of Print], G D'Haens, C Taxonera, A Lopez-Sanroman, P Nos, S Danese, A Armuzzi, X Roblin, L Peyrin-Biroulet, R West, WGN Mares, M Duijvestein, KB Gecse, BG Feagan, G Zou, MS Hulshoff, A Mookhoek, L Oldenburg, E Clasquin, Y Bouhnik, D LaharieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.